Background {#Sec1}
==========

Mesenchymal stromal cells are attractive for regenerative medicine and immunotherapy due to their multilineage and immunomodulatory potential \[[@CR1]--[@CR3]\]. However, the application of MSCs in cell therapy is often limited by low cell numbers and low proliferation rates. Therefore, finding a suitable cell source has been a major challenge in recent years \[[@CR4]\]. Although MCSs are primarily isolated from bone marrow (BM) \[[@CR5]\], several tissues, such as adipose tissue (AT) \[[@CR6]\], cord blood (CB) \[[@CR7]\], dental pulp \[[@CR8]\] and placenta \[[@CR9]\], have been proposed as alternative sources. Skin has also been reported to be a source of MSCs \[[@CR10]\], and foreskin (FSK) seems to be particularly enriched in MSCs \[[@CR11]\]. Therefore, we previously demonstrated that FSK-MSCs are a more suitable cellular product for cell therapy \[[@CR12]\]. Though previously regarded as waste, these cells have shown great potential for stem cell-based anti-tumor therapy \[[@CR13], [@CR14]\]. In this regard, it is important to establish distinct subsets of MSCs with specific therapeutic features to be used for cell-targeted therapy. Although many studies have addressed the isolation and characterization of sub-populations of MSCs \[[@CR6], [@CR15], [@CR16]\], little is known about FSK-MSCs. Aldehyde dehydrogenase (ALDH) activity is increasingly being used as a means to isolate stem or progenitor cells \[[@CR17], [@CR18]\]. ALDH enzymes are involved in several cellular properties such as self-protection, proliferation and differentiation \[[@CR17], [@CR19]--[@CR23]\].

In the present study, we combined the ALDEFLUOR™® assay \[[@CR24]\] and fluorescence activated cell sorting (FACS) \[[@CR25]\] to identify and isolate MSCs based on their ALDH activity. Consequently, two populations of FSK-MSCs (referred to as ALDH^+^ and ALDH^−^) were obtained and characterized based on their gene expression profiles in relation to the major properties of MSCs. Thus, we highlight differential gene expression profiles with respect to stemness, proliferation, phenotype, immunomodulation, hypoxia response ability, hematopoietic support and multilineage capacity according to ALDH activity in FSK-MSC subsets.

In summary, 2 distinct subsets of FSK-MSCs that harbor specific gene profiles can be identified based on their ALDH activity. Conducting functional studies may therefore confirm therapeutic relevance.

Results {#Sec2}
=======

ISCT compliance of FSK-MSCs {#Sec3}
---------------------------

The cells from FSK cultures showed the typical fibroblast-like shape with a high capacity to adhere to plastic. Immunophenotyping of the cells by flow cytometry demonstrated positivity (\> 95%) for CD73, CD90 and CD105 but lack (\< 5%) of CD14, CD19, CD34, CD45 and HLA-DR expression (Fig. [1](#Fig1){ref-type="fig"}). Moreover, these cells exhibited a multilineage potential in-vitro. After 21 days of osteogenic induction, calcium deposits were observed by Alizarin red staining. After 10 days of adipogenic induction, lipid vacuoles were revealed by Oil Red O staining. After 21 days of chondrogenic induction, proteoglycans were shown by Alcian blue staining (Fig. [2](#Fig2){ref-type="fig"}). Accordingly, FSK-MSCs used in this study present the basic characteristics of MSCs.Fig. 1Representative flow cytometry analysis of FSK-MSC immunophenotype. We used a panel of fluorochrome labelled monoclonal antibodies (mAbs). Empty histograms show the background staining with isotype control mAbs, and solid histograms represent specific staining of the indicated cell surface markersFig. 2Representative images illustrating the MSC multilineage potential. Each lineage differentiation was assessed by using both specific induction medium and staining techniques

Sorting and isolation of FSK-MSCs based on ALDH activity {#Sec4}
--------------------------------------------------------

Two populations with high and low ALDH enzymatic activity were isolated (ALDH^+^ and ALDH^−^). ALDH activity was significantly different in these 2 populations: 0.45 ± 0.05 UA (Arbitrary unity) for the ALDH^−^ and 21.78 ± 1.01 UA for the ALDH^+^ population, *p* = 0.0020 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).

Gene expression analysis of ALDH-sorted FSK-MSC subsets {#Sec5}
-------------------------------------------------------

### Stemness (Nanog; octamer-binding transcription factor 4(Oct4); Rex1) (Fig. [3](#Fig3){ref-type="fig"}) {#Sec6}

Sorting for ALDH activity allowed us to distinguish ALDH^+^ and ALDH^−^ subsets based on the expression of genes related to stemness. We did not observe *Nanog* expression in either subset. We observed the up-regulation of *Oct4* (235.5 ± 17.4) in ALDH^+^ cells compared with ALDH^−^ (173.2 ± 5) cells (*p* = 0.0362). *Rex1* expression was similar between both subsets, with a slight but not significant decrease in the ALDH^−^ population (3259 ± 147.5 in ALDH^+^ vs 2759 ± 56.9 for ALDH^−^).Fig. 3Stemness-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH^+^ and ALDH^−^ FSK-MSC subsets, we investigated by qPCR the expression profiles of pluripotency-associated genes Oct4, Nanog and Rex1. Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression. *(ns = non significant)*

### Proliferation/cell cycle (CyclinA (CCNA), CCNB, CCNE; CDK1, CDK2, Fos proto-oncogene (FosB); p21; p53; p16; retinoblastoma protein (pRB); cell division cycle 25A (CDC25A); signal transducer and activator of transcription (STAT1)) (Fig. [4](#Fig4){ref-type="fig"}) {#Sec7}

ALDH^+^ and ALDH^−^ subsets demonstrated distinct gene profiles associated with proliferation/cell cycle. The ALDH^+^ subset displayed significantly higher expression of these genes. The most highly expressed genes in ALDH^+^ cells vs ALDH^−^ cells were p21 (71,794 ± 811.2 vs 50,446 ± 466.7; *p* = 0.0033), CDK1 (22,788 ± 605.1 vs 19,097 ± 415.7; *p* = 0.0219) and CCNA (29,338 ± 415.1 vs 12,854 ± 645.1; *p* = 0.0041). We observed significantly higher expression of CDK2, pRB and CDC25A in ALDH^+^ cells (6683 ± 141.5, 7643 ± 202.1, 1140 ± 24.9) cells than in ALDH^−^ cells (4722 ± 50.6, 5388 ± 113, 505.2 ± 47.1) (*p* = 0.0055, p = 0.0033, *p* = 0.0014). We also noticed weakly increased of *FosB* gene expression in ALDH^+^ cells (2592 ± 30.4) compared with ALDH^−^ cells (2283 ± 96.3). The ALDH^+^ population expressed significantly higher levels of *CCNB* and *CCNE* than the ALDH^−^ population (1532 ± 80.5 vs 1169 ± 43.9, 773.5 ± 92.7 vs 351.8 ± 14.5 with *p* = 0.0112 and *p* = 0.0364, respectively). Moreover, *STAT1* was more highly expressed in the ALDH^+^ population (1286 ± 41.9 vs 858.2 ± 58.1, *p* = 0.0337).Fig. 4Cell-cycle-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH+ and ALDH- FSK-MSC subsets, we investigated by qPCR the expression profiles of cell-cycle-associated genes *FosB, CDK2, pRB, CCNE, CDC25A, CCNA, CCNB, STAT1, P21 and CDK1*. Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression

### Phenotype (melanoma cell adhesion molecule CD146 (MCAM); CD200; vascular cell adhesion molecule 1 CD106 (VCAM-1); intercellular adhesion molecule 1 CD54 (ICAM-1); CD58 (LFA-3)) (Fig. [5](#Fig5){ref-type="fig"}) {#Sec8}

ALDH^+^ and ALDH^−^ subsets showed several gene expression differences with respect to the MSC phenotype. First, CD146 and CD200 were not found in either subset. CD54, CD58 and CD106 were most highly expressed in ALDH^+^ cells (5218 ± 12.1, 9135 ± 52.7, 550.4 ± 16.8 respectively) compared with ALDH^−^ cells (4403 ± 12.9, 7211 ± 30.2, 148.3 ± 10.6, respectively) with significant *p*-values (*p* = 0.0008, *p* = 0.0013, *p* = 0.0003, respectively).Fig. 5Phenotype-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH+ and ALDH- FSK-MSC subsets, we investigated by qPCR the expression profiles of phenotype-associated genes *CD54, CD58 and CD106*. Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression

### Hypoxia response (hypoxia-inducible factor (HIF)-1α; HIF-2α; solute carrier family 2 member 1 (GLUT1)) (Fig. [6](#Fig6){ref-type="fig"}) {#Sec9}

Consistent with their ALDH activity, the expression of genes involved in the hypoxia response was significantly different between the ALDH^+^ and ALDH^−^ subsets. *HIF1α, HIF2α* and *GLUT1* expression levels were higher in ALDH^+^ cells (675.5 ± 36.6 vs 529.7 ± 8.1, 17,258 ± 431.9 vs 7354 ± 341.3, 53,748 ± 3251 vs 37,335 ± 3397, respectively), and all had significant p-values except for *HIF1α* (*p* = 0.0525, *p* = 0.0027, *p* = 0.0057, respectively).Fig. 6Hypoxia-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH+ and ALDH- FSK-MSC subsets, we investigated by qPCR the expression profiles of hypoxia-associated genes *HIF1α, HIF2α and GLUT1*. Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression. *(ns = non significant)*

### Angiogenesis [(]{.ul}angiopoietin (ANG)1, ANG2, Fms-related tyrosine kinase 1 (FLT1); vascular endothelial growth factor (VEGF)) (Fig. [7](#Fig7){ref-type="fig"}) {#Sec10}

ALDH^+^ and ALDH^−^ cells had distinct gene expression profiles associated with angiogenesis. ANG2 was not expressed by either subset. Compared with ALDH^−^ cells, ALDH^+^ cells showed significantly higher levels of ANG1 (887.3 ± 9.2 vs 498.5 ± 12.9), FLT1 (57.87 ± 17.8 vs 2867 ± 14.5) and VEGF (18,854 ± 508.6 vs 15,098 ± 429.2). Thus, ALDH^+^ cells appear to exhibit highly angiogenic properties.Fig. 7Angiogenesis-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH+ and ALDH- FSK-MSC subsets, we investigated by qPCR the expression profiles of angiogenesis-associated genes *FLT1, ANG1 and VEGF*. Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression

### Hematopoietic support (matrix metalloproteinase 2 (MMP2); stromal derived factor 1 (SDF1); kit ligand (SCF); Interleukin-6 (IL-6); IL-8) (Fig. [8](#Fig8){ref-type="fig"}) {#Sec11}

ALDH^+^ and ALDH^−^ cells subsets showed significant differences in genes linked to the hematopoietic supporting capacity of FSK-MSCs. *MMP2, SCF, SDF1, IL-6 and IL-8* were strongly expressed in the ALDH^+^ subset (762,594 ± 68,274, 62,691 ± 4273, 155,209 ± 6358, 142,246 ± 1405 and 41,120 ± 806.3) compared with ALDH^−^ cells (404,009 ± 6630, 30,176 ± 800.4, 130,426 ± 2144, 78,498 ± 2771 and 33,115 ± 1102) (*p* = 0.0393, *p* = 0.0124, *p* = 0.0324, *p* = 0.0026 and *p* = 0.0018, respectively).Fig. 8Pro-hematopoietic-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH+ and ALDH- FSK-MSC subsets, we investigated by qPCR the expression profiles of pro-hematopoietic-associated genes *SDF1, MMP2, SCF, IL6 and IL8*. Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression

### Immunomodulation capacity (Galectin1 (GAL1); hepatocyte growth factor (HGF); leukemia inhibitory factor (LIF); cyclooxygenase (COX)1 and COX2) (Fig. [9](#Fig9){ref-type="fig"}) {#Sec12}

ALDH^+^ and ALDH^−^ subsets had different immunoregulatory gene expression patterns. These genes were more highly expressed in ALDH^+^ cells than in ALDH^−^ subsets: 1.1 × 10^6^ ± 23,780 vs 526,797 ± 39,702 for GAL1 (*p* = 0.0077), 35,740 ± 2110 vs 17,626 ± 1027 for *COX1* (*p* = 0.0056), 20,484 ± 366.2 vs 16,219 ± 551.6 for *COX2* (*p* = 0.0282), 2655 ± 84 vs 850.7 ± 69.2 for *HGF* (*p* = 0.0067) and 2615 ± 161.8 vs 1236 ± 129.8 for LIF (*p* = 0.0133).Fig. 9Immunomodulatory-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH+ and ALDH- FSK-MSC subsets, we investigated by qPCR the expression profiles of pro-hematopoietic-associated genes *COX1, COX2, HGF, LIF and GAL1*. Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression

### Multilineage competence (Fig. [10](#Fig10){ref-type="fig"}) {#Sec13}

A.Chondrogenesis potential (Sry box 9 (Sox9); Collagen type II alpha 1 chain (Col2a1); Aggrecan (ACAN); Cartilage Oligomeric matrix protein (COMP)). Fig. 10Multilineage-related gene expression profile of FSK-MSC subsets according to ALDH activity. After flow cytometry sorting of ALDH+ and ALDH- FSK-MSC subsets, we investigated by qPCR the expression profiles of multilineage-associated genes such as COL2a1, SOX9, CAN, COMP for chondrogenesis (**a**), Runx2, OPN, OPG for osteogenesis (**b**) and PPARγ, KLF2, KLF5, CEBPα, CEBPδ for adipogenesis (**c**). Data are presented as mean ± SEM of mRNA gene expression relative to *GAPDH* expression. *(ns = non significant)*

ALDH^+^ and ALDH^−^ cells demonstrated distinct gene expression profiles with respect to chondrogenic potential. We observed no significant difference between these subsets regarding *COL2α1* expression. Meanwhile, *ACAN* (589,668 ± 21,737 vs 268,260 ± 16,493, *p* = 0.0059), Sox9 (2206 ± 23.8 vs 1715 ± 30.5, *p* = 0.0114 and COMP (3702 ± 156.4 vs 487.5 ± 30.3, *p* = 0.0021) expression were significantly higher in ALDH^+^ cells than in ALDH^−^ cells.B.Osteogenesis potential (Runt related transcription factor 2 (Runx2); Osterix (OSX); Integrin binding sialoprotein (BSP); TNF receptor superfamily member 11 (OPG); Secreted phosphoprotein type 1 (OPN)).

The osteogenic gene profiles of ALDH^+^ and ALDH^−^ cell subsets were substantially different. BSP and OSX were not expressed in either subset. Runx2 (53,180 ± 3959 vs 16,386 ± 619.6, *p* = 0.0089), OPG (609,334 ± 25,983 vs 526,399 ± 20,205, *p* = 0.0064) and OPN (1698 ± 14 vs 1093 ± 44.8, *p* = 0.0026) were more highly expressed in ALDH^+^ cells than in ALDH^−^ cells.C.Adipogenesis potential [(]{.ul}CCAAT/enhancer binding protein alpha (C/EBP-α), C/EBP-δ; Peroxisome proliferator activated receptor gamma (PPAR-γ); Kruppel like factor (KLF2); KLF5; Adiponectin (ADIPOQ)).

The majority of the genes linked to adipogenesis were differentially expressed by the ALDH^+^ and ALDH^−^ subsets. *ADIPOQ* was not expressed at all. Adipogenesis genes were most highly expressed in ALDH^+^ cells: 12323 ± 684.3 vs 3332 ± 306 for PPARγ, 12,411 ± 564.1 vs 3666 ± 43.9 for KLF2, 445.9 ± 20.2 vs 229.8 ± 12.9 for KLF5, 136.1 ± 6.1 vs 86.9 ± 4.5 for CEBPα and 106.6 ± 3.2 vs 90.9 ± 4 for CEBPδ (*p* = 0.0019, *p* = 0.0043, *p* = 0.0221, *p* = 0.0194 and *p* = 0.0260).

Discussion {#Sec14}
==========

MSCs can be isolated from both adult and fetal tissues \[[@CR26]--[@CR29]\] and may share basic characteristics \[[@CR30]\]. However, these MSCs may have some differences probably related to their distinct gene and protein profiles \[[@CR31], [@CR32]\]. As a potential alternative source of MSCs, FSK tissue has recently emerged as a promising candidate for different cell-based therapies \[[@CR12], [@CR13], [@CR33]\]. Consequently, we have demonstrated that FSK contains a high number of immunotherapeutic MSCs \[[@CR12]\]. However, different sub-populations of MSCs with specific features might be observed \[[@CR6]\]. Of Importance, understanding the product profile of the intended therapy is crucial to achieving the desired therapeutic effect \[[@CR34], [@CR35]\]. Different enrichment methods to obtain MSCs are reported in the literature with contrasting results \[[@CR36]\]. Thus, no single surface marker is currently available to identify and isolate MSCs from various tissue environments that could be therapeutically relevant \[[@CR37]\]. Therefore, finding a suitable method to identify subsets of MSCs with distinct features is of high priority to ensure efficient therapy.

In this regard, ALDH activity has been shown to be important for the biology of stem and progenitor cells \[[@CR17]\]. In MSCs, ALDH activity is critical for tissue repair and regeneration \[[@CR38]--[@CR40]\]. In addition, ALDH activity and expression appear to be promising markers and potential therapeutic targets for treating many malignancies \[[@CR41]\]. A recent study reported that low expression of ALDH in decidual MSC (DMSC) isolated from preeclamptic (PE) patients is associated with reduced resistance to cell toxicity. In line, stem and progenitor cells expressing high level of ALDH were shown to be clinically safe and effective cell therapy for peripheral ischemia \[[@CR42]\]. These cyto-protective enzymes may thus potentiate cell therapy by serving as markers of highly therapeutic MSCs that harbor specific competencies.

Using FACS, we were able to sort two subsets of FSK-MSCs (e.g., ALDH^+^ and ALDH^−^) based on their ALDH activity. Several tissue-dependent progenitors with high ALDH activity have been reported to be therapeutically relevant because they harbor specific biological functions such as tissue repair and hematopoietic reconstitution \[[@CR19]\]. The global gene expression profiles of a variety of non-hematopoietic progenitors are likely to have an important impact on their properties as well as on their cellular therapeutic applications \[[@CR43]\]. Accordingly, depending on their ALDH activity, these FSK-MSC subsets demonstrated distinct transcriptional profiles for genes associated with major MSC properties (e.g., proliferation, response to hypoxia, angiogenesis, phenotype, stemness, multilineage, hematopoiesis, and immunomodulation) \[[@CR8], [@CR44]--[@CR47]\]. As discussed below, these gene expression differences between FSK-MSCs subsets may indicate specific biological features with considerable therapeutic relevance.

In terms of stemness \[[@CR48]\], Nanog was not expressed in either FSK-MSC subset, while Rex1 and Oct4 were more highly expressed in ALDH^+^ cells than in ALDH^−^ cells. These genes appear to be crucial for the efficient maintenance of cell pluripotent identity \[[@CR49]\]. Our observations were consistent with the work of Dey and colleagues, which suggested that fetal heart-derived cells with high ALDH activity exhibit enhanced gene expression for self-renewal, proliferation, and survival \[[@CR50]\].

Regarding the cell cycle, we observed substantial differences in FosB, CDK1, CDK2, pRB, CCNA, CCNB, CCNE, CDC25A and p21 expression. All of these targets were highly upregulated in ALDH^+^ cells. The cell cycle is likely to be influenced by ALDH activity and is likely critical for cell specificity and the properties of different cellular populations \[[@CR45], [@CR51], [@CR52]\]. Mechanistically, ALDH has been implicated in controlling cell proliferation during the catabolism of endogenous substrates that have the capacity to either stimulate or inhibit the expression of genes involved in the cell cycle \[[@CR53]\].

An important issue for optimal cell-based therapy is the phenotype of the cellular product being used \[[@CR54]\]. Progenitors cells generally express similar markers regardless of their tissue of origin, with difference being largely restricted to CD54, 58, 106, 146 and CD200 \[[@CR18], [@CR55]--[@CR57]\]. Here, we notably observed increased CD54, 58 and 106 expressions in ALDH^+^ FSK-MSCs. The expression of the primary adhesion molecules CD54 and CD58 has been reported to vary according to the MSC source \[[@CR18], [@CR19]\]. Cells with CD54 expression were shown to have high immunosuppressive capacity \[[@CR58]\]. Interestingly, CD106 expression was even restricted to specific tissues \[[@CR59]\] and was suggested to have distinct immunomodulatory abilities \[[@CR60]\] and pro-angiogenic potential \[[@CR61]\]. The absence of CD146 and CD200 expression in FSK-MSCs subsets is likely dependent on the tissue of origin and the MSC environment \[[@CR56], [@CR62], [@CR63]\]. The enrichment of CD200 may also have a significant impact on immunomodulation \[[@CR55]\], regenerative potential \[[@CR64]\] and osteogenesis in a subset of progenitor cells \[[@CR63]\]. As a mesenchymal marker, CD146 was shown to define subsets of cells of different origin with remarkable stemness, multilineage potential and immunomodulatory capacities \[[@CR65]\].

During tissue repair, the hypoxia-induced activation of HIFs regulates different cellular functions such as angiogenesis and inflammation \[[@CR66], [@CR67]\]. In ALDH^+^ cells, a significant increase in HIF2α, GLUT1 and, to a lesser extent, HIF1α expression was observed. Gene responses to hypoxia are cell-type specific, and HIFs have been implicated in stemness \[[@CR68], [@CR69]\]. In parallel, high ALDH activity enhanced stem-cell features in breast cancer cells by activating HIF2α expression \[[@CR70]\], suggesting a crucial role for ALDH in targeted therapies. With regard to hypoxia, ALDH expression in MSCs is required for cellular resistance to oxidative stress \[[@CR38]\]. ALDH activity clearly influences HIF gene expression patterns to allow for appropriate MSC responses to hypoxia. The expression of HIF1α and GLUT1 genes was higher in ALDH^+^ cells confirming their importance for cell-response to hypoxia. Thus, the therapeutic efficiency of ALDH^+^ cells was observed in patients with chronic myocardial ischemia and critical limb ischemia \[[@CR71], [@CR72]\].

Based on their ALDH activity, MSCs promote angiogenesis as a part of their tissue repair and regeneration capability \[[@CR66]\]. MSCs with high ALDH activity are likely to be more responsive to hypoxia by upregulating FLT1, CXCR4, and ANG2 \[[@CR56]\]. Indeed, we observed increased expression of angiogenic genes (ANG1, FLT1 and VEGF) in ALDH^+^ cells. However, ANG2 was not expressed in FSK-MSCs. Vishnubalaji and colleagues demonstrated that FSK-MSCs exhibit high tube-forming capability (similar to endothelial cells from the human umbilical vein) \[[@CR56]\]. MSCs from non-FSK tissues that harbor high ALDH activity were shown to have the ability to home to damaged tissues and promote angiogenesis, thus protecting mice against acute ischemic injury \[[@CR19]\]. By showing significantly higher levels of ANG1, FLT1 and VEGF, ALDH^+^ cells may exhibit potent angiogenic properties that have proved to be therapeutically relevant. Indeed, human BM ALDH^+^ cells were able to improve perfusion in ischemic limbs after transplantation (showed augmented recovery of perfusion and increased blood vessel density) \[[@CR73]\].

MSCs also play an important role in the homeostasis of the hematopoietic system by generating most of the stromal cells that are present in the hematopoietic stem cell (HSC) niche and by providing different factors that regulate hematopoiesis, such as IL6, IL8, MMP2 and SCF \[[@CR74]\]. We found that ALDH^+^ FSK-MSC subsets may exhibit potent hematopoiesis-supporting abilities following IL6, IL8, SCF, SDF1 and MMP2 up-regulation and these results corroborate the fact that ALDH activity may be used as a surrogate marker for hematopoietic stem cell transplant activity \[[@CR75]\]. As suggested previously, IL-8, rather than IL-6, may mechanistically support the engraftment of repopulating cells by enhancing MMP-2 expression and therefore increasing migration and infiltration within BM \[[@CR76]\].

FSK-MSCs are likely to be considered immunotherapeutic cells \[[@CR12]\], and their immunomodulatory properties may actively account for their tissue repair activity \[[@CR77]\]. MSCs can modulate the immunological functions of several immune cell populations both in vitro and in vivo \[[@CR78], [@CR79]\]. However, distinct types of MSCs have been shown to display specific immunomodulatory characteristics \[[@CR9], [@CR80]\]. Here, ALDH^+^ FSK-MSCs subsets showed elevated COX1/2, GAL1, LIF and HGF expression, suggesting better immunomodulatory features that might be more attractive for immunotherapeutic interventions. Indeed, all of these factors were previously described to actively compete in establishing a tolerogenic state sustained by MSCs \[[@CR81]\]. Accordingly, ALDH was shown to be critical for the induction of Tregs, thus promoting immunological tolerance \[[@CR82]\].

FSK-MSCs are capable of differentiating into several lineages and are thus relevant for regenerative cell therapy \[[@CR14], [@CR57]\]. We have therefore examined the expression of the major genes associated with the tri-lineage potential of MSCs \[[@CR83], [@CR84]\]. For osteogenesis, we did not observe OSX or BSP expression in either subset, whereas OPG, OPN and Runx2 were more highly expressed in ALDH^+^ cells, suggesting that this population has a higher capacity to differentiate into osteoclasts than ALDH^−^ cells. Moreover, FSK cells have been shown to display osteogenesis capacity and participate to bone repair \[[@CR85], [@CR86]\]. De Kock and colleagues demonstrated that FSK cells are the most appropriate stem cells for bone-based applications compared with other types of MSCs \[[@CR43]\]. Increased ALDH levels are associated with enhanced stress resistance and muscle regeneration capacity in muscle-derived cell progenitors \[[@CR84]\]. ALDH^+^ MSCs from umbilical cord blood had a greater ability to differentiate and their transplantation into fractured mouse femurs enabled early repair of tissues and rapid bone substitution \[[@CR87]\]. Compared to cells with low activity (ALDH^−^), the ALDH^+^ sub-population of murine \[[@CR88]\] and canine \[[@CR89]\] cells exhibited a higher capacity for osteogenic and adipogenic differentiation.

As for adipogenesis, Li and colleagues showed that FSK-MSCs can be differentiated into adipocytes and osteocytes \[[@CR13]\]. This ability appeared to be more prominent in ALDH^+^ FSK-MSCs, which expressed significantly higher levels of adipogenic markers such as CEBPα, CEBPδ, PPARγ, KLF2, and KLF5 \[[@CR90]--[@CR92]\].

Finally, we evaluated the ability of FSK-MSCs to differentiate into chondroblasts \[[@CR93], [@CR94]\]. ALDH^+^ cells expressed higher levels of chondrogenic genes (Sox9, ACAM, COMP). However, ALDH activity may not be relevant for chondrogenesis capacity in MSCs \[[@CR95]\]. These observations suggest that ALDH^+^ FSK-MSC subsets may differ in their differentiation capacity depending on the tissue context and may thus play a significant role in regenerative medicine. As discussed by Dollé et al. \[[@CR96]\], although ALDH isoforms may be used as cell markers, they play different roles in stem/progenitor cell populations.

Conclusion {#Sec15}
==========

In the present work, the use of ALDH activity to identify FSK-MSC subsets with specific gene profiles is feasible and may become therapeutically relevant once functional studies have been conducted.

Methods {#Sec16}
=======

Isolation, culture and characterization of FSK-MSCs {#Sec17}
---------------------------------------------------

This study was approved by the Bordet Institute Ethics Committee (Belgium) and conducted in accordance with the Declaration of Helsinki (1964). Three FSK samples were obtained following a circumcision procedure and all donors and/or their parents gave written informed consent. All the procedures for the isolation, culture and characterization of FSK-MSCs were conducted according to our previously study \[[@CR12]\]. Briefly, after the surgical procedure, FSK samples were collected into a sterile specimen container containing sterile phosphate-buffered saline (PBS; Lonza) supplemented with penicillin/streptomycin (Lonza). After a wash with sterile PBS, the FSK was sectioned longitudinally to spread the tissue and the epidermis was manually removed from the skin. The dermis was cut into small pieces and tissue dissociation was applied with enzymatic digestion by incubation for 1 h at 37 °C with 0.2 mg/mL of Liberase Research Grade solution (Roche Diagnostics). After digestion step, 10% fetal bovine serum (FBS; Sigma-Aldrich) was added to neutralize the enzymes, and the cell suspension was washed by centrifugation (800 g for 5 min at room temperature) in Dulbecco's Modified Eagle's Medium with low glucose (DMEM-LG; Lonza). The resulting cell pellet was then seeded in culture flasks with DMEM-LG (Lonza) supplemented with 10% FBS (Sigma-Aldrich), 2 mmol/L L-glutamine and 50 U/mL penicillin/streptomycin (both from Lonza). Cell cultures were maintained at 37 °C in a 5% CO2 humidified atmosphere. When sub-confluence (80--90%) was achieved, adherent cells were harvested by TrypLE Select (Gibco, LifeTechnologies) and expanded until the second passage (P2). The characterization of FSK-MSCs was achieved according to the ISCT criteria. Both immunophenotype and multilineage potential were thus confirmed. Briefly, the immunophenotype was determined by flow cytometry analysis using a panel of fluorochrome labelled monoclonal antibodies against membrane markers. The multilineage potential was demonstrated by culturing FSK-MSCs in appropriate induction medium and by using specific coloration to show their adipogenic, osteogenic and chondrogenic differentiation capacities (more details presented in Additional file [1](#MOESM1){ref-type="media"}).

Fluorescence activated cell sorting analysis (FACS) {#Sec18}
---------------------------------------------------

Cell sorting was conducted using a FACS-Aria (BD Biosciences, San Jose, CA) as it has been previously described \[[@CR97]\]. The instrument quality control was checked on a daily basis throughout by using Cytometer setting and tracking beads (CS&T) and software (FACSDiva). A primary gate was placed on the scatter population and a second one for PI (Propidium iodide) (Fluka, 70,335) negative cells allowing thus to analyze only live cells excluding residual erythrocytes and debris. We also have incorporated a doublet discriminating gate based upon height versus area of the side scatter signals. These settings were then used throughout the assay. Analysis was done using the Flo-Jo program (Tree Star, Ashland, <https://www.flowjo.com/>).

Detection, study and sorting of FSK-MSCs based on their ALDH activity {#Sec19}
---------------------------------------------------------------------

Fluorescent ALDH substrate (BODIPY® - aminoacetaldehyde (BAAA/ALDEFLUOR™ kit) (StemCell Technologies) is used to identify and isolate a population with high ALDH versus low ALDH enzymatic activity (hereafter referred to as ALDH^+^ and ALDH^−^) according to our previous report (see \[[@CR96], [@CR97]\] for further information). As a non-polar fluorescent molecule, BAAA is taken up by viable cells through passive diffusion. The BAAA is composed of 2 parts: the Bodipy molecule which contains the green fluorescence and the amino-acetaldehyde which is the substrate for ALDH1A1. BAAA could be metabolized by this isoform \[[@CR98]\] to a carboxylate fluorescent ion BAA^−^ which is retained intracellularly, allowing thus to sort by FACS cells demonstrating high levels of ALDH activity (the assay buffer used for analysis contains an efflux inhibitor; for further information, see (<http://www.aldh.org>/)).

Dissociated single cells (with trypsin) were suspended in ALDEFLUOR™ assay buffer containing the BAAA (1 μM per 3 × 10^6^ cells) and incubated at + 37 °C without agitation during 50 min. ALDEFLUOR™ staining was performed three times for each sample. The sorting gate of the ALDH^+^ cells was established using DEAB-treated cells as a reference. For all subsequent procedures, samples were constantly maintained at + 4 °C to prevent efflux. ALDEFLUOR™ fluorescence was excited at 488 nm, and fluorescence emission was detected using a standard fluorescein-isothiocyanate 530/30 nm band-pass filter. All samples were thus sorted into 2 different collector tubes, namely "ALDH^+^" and "ALDH^−^".

Gene expression profiling by real time PCR (qPCR) {#Sec20}
-------------------------------------------------

Immediately after the sorting, the cells were spin down by centrifugation. The cell lysate buffer (10 mL of BL-buffer from Promega (ref Z103c) was mixed with 10 μL of thioglycerol (ref A208B)) to perform the extraction of the total mRNA. Since the number of cells obtained after the cell sorting were roughly small for some populations, we used the RNeasy micro kit (ref 74,004) from Qiagen to ensure optimal RNA purification. We performed the reverse transcription reaction with 1 mg RNA using qScript cDNA SuperMix (Quanta Biosciences). Transcripts were quantified by qRT-PCR using 10 ng of cDNA, SYBR Green PCR Master Mix (Applied Biosystems, Lennik, Belgium) and 0.32 mM forward and reverse primers. The primers were designed with Primer Express 2.0 software (Applied Biosystems) or ProbeFinder online software (Roche) and are available in Additional file [1](#MOESM1){ref-type="media"}: Table S1. For qPCR analysis, each condition has been run in triplicate. To control variations in input RNA amounts, the GAPDH gene was used as a housekeeping gene to quantify and normalize the results. The reactions were carried out using the ABI Prism 7900 HT system (Applied Biosystems). In all cases, dissociation curves were generated and the specificity of the PCR reactions was confirmed. The comparative ΔΔCt method was used for the data analysis. To evaluate the fold change, data were normalized with the GAPDH genes to obtain the ΔCt and were after calibrated with the geometric mean of the GAPDH ΔCt to generate the ΔΔCt. Fold changes were then calculated as fold change = 2^-ΔΔCt^.

Statistical analysis {#Sec21}
--------------------

Data are presented as mean ± standard error of the mean (SEM). Comparison between sorted fractions was evaluated with the matched paired t test. *p* values \< 0.05 were considered as statistically significant. All analyses were performed with GraphPad Prism version 5.00 for windows (GraphPad Software, [www.graphpad.com](http://www.graphpad.com)).

Additional file
===============

 {#Sec22}

Additional file 1:Supplemental data. (DOC 8200 kb)
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